Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
02/14/2023* -- Results Q1 2023 -- -- --
05/13/2022 -- Results Q2 2022 -- -- --
02/14/2022 -- Results Q1 2022 -- -- --
08/13/2021 -- Results Q3 2021 -0.46 -0.14 -227.0%
05/14/2021 -- Results Q2 2021 -0.81 -0.39 -107.7%
02/16/2021 -- Results Q1 2021 -0.26 -0.22 -18.18%
12/07/2020 -- Results Q4 2020 -0.22 -0.23 4.35%
08/12/2020 -- Results Q3 2020 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 02/14/2023 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 05/13/2022
Beat/Miss Upgrade
Return Since 5.95%
Last FQE 03/31/2022
Next FQE 06/30/2022

Profile

Edit
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side-effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.
URL https://www.edesabiotech.com
Investor Relations URL http://ir.stellarbiotechnologies.com/
HQ State/Province Ontario
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Feb. 14, 2023 (est.)
Last Earnings Release May. 13, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio --
Cash Payout Ratio --
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
-44.04%
-68.72%
-60.09%
-83.95%
-24.91%
3.66%
32.47%
-65.19%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-8.98%
-32.14%
-14.98%
115.7%
50.55%
197.1%
-31.74%
65.37%
-62.26%
110.0%
93.75%
445.2%
-44.97%
-58.87%
-34.82%
-46.12%
-20.60%
47.27%
-31.65%
-37.82%
-81.28%
-95.69%
-49.88%
-74.05%
-49.54%
-59.29%
-4.23%
-63.31%
123.4%
107.8%
17.32%
103.1%
20.26%
As of August 15, 2022.

Profile

Edit
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side-effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.
URL https://www.edesabiotech.com
Investor Relations URL http://ir.stellarbiotechnologies.com/
HQ State/Province Ontario
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Feb. 14, 2023 (est.)
Last Earnings Release May. 13, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

No data available
Symbol Dollars Invested % Weight
     
     
     
     
     
     
     
     
     
     

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter EDSA Tweets